CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Serum Testosterone Level as Possible Predictive Marker for Prognosis in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Enzalutamide

Dong Hyeon An, Hwiwoo Kim, Donghyun Lee, In Gab Jeong, Dalsan You, Jun Hyuk Hong, Choung-Soo Kim, Hanjong Ahn

Korean J Urol Oncol. 2021;19(1):60-69. Published online 2021 February 26 DOI: https://doi.org/10.22465/kjuo.2021.19.1.60

Serum Testosterone Level as Possible Predictive Marker for Prognosis in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Enzalutamide

Dong Hyeon An, Hwiwoo Kim, Donghyun Lee, In Gab Jeong, Dalsan You, Jun Hyuk Hong, Choung-Soo Kim, Hanjong Ahn

The Korean Journal of Urological Oncology. 2021;19(1):60-69

Link1

Link2 Link3

Enzalutamide for patients with metastatic castration-resistant prostate cancer

Wijdan Ramadan, Wissam Kabbara, Hiba Al Basiouni Al Masri

OncoTargets and Therapy. 2015;871

Link1

Enzalutamide in Metastatic Castration Resistant Prostate Cancer

Jeffrey Shevach, Bridget K. Marcellino, William K. Oh, Che-Kai Tsao

Managing Metastatic Prostate Cancer In Your Urological Oncology Practice. 2016;157-169

Link1

232P Real-world data on metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: A regional experience

R. Raju, A. Sahu, M. Klevansky, J. Torres

Annals of Oncology. 2020;31:S1332

Link1 Link2

Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer: A retrospective study

Takeshi Azuma

The Prostate. 2018;78(4):278-278

Link1 Link2

Cost-Utility Analysis of Enzalutamide for Patients with Previously Treated Metastatic Castration-Resistant Prostate Cancer (MCRPC)

C. Vicente, V. Babashov, F. Husein, F. Saad, S. Naidoo, S. Holmstrom

Value in Health. 2014;17(3):A89-A90

Link1 Link2

Correction to: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate

Scott T. Tagawa, Krishnan Ramaswamy, Ahong Huang, Jack Mardekian, Neil M. Schultz, Li Wang, Rickard Sandin, Stanislav Lechpammer, Daniel J. George

Prostate Cancer and Prostatic Diseases. 2022;

Link1

Link2 Link3

Higher serum testosterone levels predict poor prognosis in castration‐resistant prostate cancer patients treated with docetaxel

Keisuke Ando, Shinichi Sakamoto, Nobushige Takeshita, Ayumi Fujimoto, Maihulan Maimaiti, Shinpei Saito, Pae Sanjyon, Yusuke Imamura, Nobuo Sato, Akira Komiya, Koichiro Akakura, Tomohiko Ichikawa

The Prostate. 2019;80(3):247-255

Link1 Link2 Link3 Link4

344 Phase 3 trial of pembrolizumab and enzalutamide versus enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) (KEYNOTE-641)

Julie Nicole Graff, Joseph Burgents, Li Wen Liang, Arnulf Stenzl

Regular and young investigator award abstracts. 2020;

Link1

Enzalutamide: A Review of Its Use in Metastatic, Castration-Resistant Prostate Cancer

Mark Sanford

Drugs. 2013;73(15):1723-1732

Link1

Link2 Link3